Medical Oncology

COVID-19

Questions discussed in this category

Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

1 Answer available

Do you routinely check platelet counts after COVID-19 vaccines in patients with chronic ITP?

1 Answer available

Do you recommend COVID vaccination in patients with antiphospholipid antibody positivity or other prothrombotic states not on anti-coagulation?

1 Answer available

What hematologic conditions are contraindications for a COVID vaccine?

2 Answers available

How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?

1 Answer available

In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?

2 Answers available

How do you advise a patient with VTE on indefinite anticoagulants regarding the Ad26.COV2.S Johnson & Johnson/Janssen COVID vaccine?

1 Answer available

Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

3 Answers available

Is the COVID-19 pandemic affecting your choice of high dose versus weekly cisplatin for definitive concurrent chemoradiation for HPV negative head and neck cancer?

1 Answer available

What are the current official guidelines regarding COVID-19 vaccination for patients with cancer or for hematologic conditions?

2 Answers available

How would you time COVID-19 vaccination with someone on R-CHOP chemotherapy?

1 Answer available

What are best practices for radiation oncology patient and staff precautions with the COVID-19 pandemic?

I know many centers are exercising extra precautions in light of the new concerns with coronavirus. How are people explaining things to their patients...

12 Answers available

How long should breast cancer patients whose surgeries are delayed due to COVID-19 remain on neoadjuvant endocrine therapy?

For patients with low risk, early stage, HR+/HER2- breast cancer who initiated endocrine therapy in order to delay their surgery due to the COVID 19 e...

3 Answers available

What is your strategy for having COVID positive patients resume infusions after they have recovered from the infection?

1 Answer available

Are there scenarios that new visits/consults with patients can be done virtually amidst the COVID-19 outbreak?

6 Answers available

How will your management of head and neck cancers change with the COVID-19 pandemic?

Are you employing more or less primary chemoRT v. surgery for some cancers? Are you dose de-escalating? What are issues radiation oncologists should b...

6 Answers available

Should new patients requiring chemotherapy be tested for COVID-19 prior to starting treatment?

1 Answer available

In the setting of COVID-19, would you perform a SLNB for a patient incidentally found to have microinvasive ER+ ILC in contralateral prophylactic mastectomy following neoadjuvant chemotherapy for a locally advanced triple positive breast cancer?

2 Answers available

How do you approach the decision of whether and when to initiate therapy in patients who remain COVID-19 positive >2 weeks after infection but are asymptomatic from the virus?

E.g. a patient with progression of their primary cancer but still is testing COVID19+ over a month after infection?

5 Answers available

Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?

Are you placing more weight on patient risk factors such as age >65 or co-morbidities?

2 Answers available

Would you hold rituximab for newly diagnosed B-cell lymphoma if the patient is COVID-19 positive?

What if the patient has a history of confirmed COVID-19 but has since recovered?

1 Answer available

Should maintenance rituximab be held due to COVID-19 in patients with advanced bulky follicular lymphoma who attain a PR/CR to weekly rituximab?

1 Answer available

What neoadjuvant therapy would you choose for a post menopausal woman with ER negative, PR positive high grade node negative breast cancer?

Would you consider genomic assays before neoadjuvant chemotherapy? How would you modify your treatment given the COVID-19 pandemic?

5 Answers available

What are best practices for taking care of lung cancer patients during the COVID-19 pandemic?

4 Answers available

What is your preferred neoadjuvant chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) and duration for a resectable T2N1 pancreatic adenocarcinoma in a fit patient whose surgery has been cancelled due to COVID-19 risk in the hospital?

1 Answer available

Due to the thrombotic nature of COVID-19, should we be discontinuing tamoxifen temporarily in patients with an active infection?

1 Answer available

Would you withhold immunotherapy for ES-SCLC during the COVID-19 pandemic?

What are the risks of infection with COVID-19 if using immunotherapy?

2 Answers available

Should our selection for neoadjuvant chemotherapy in ovarian cancer patients change in light of COVID-19?

1 Answer available

Would you choose neoadjuvant endocrine therapy for a low grade, node negative, ER/PR positive, breast cancer given delays in definitive surgery due to the COVID-19 pandemic?

Would your choice vary based on the patient's gender?

1 Answer available

Are maintenance therapies for ovarian cancer being held at your institution due to COVID-19?

2 Answers available

How are you modifying your current sarcoma-directed therapy in the setting of the COVID-19 pandemic?

For example, would you consider switching to an outpatient regimen in lieu of AIM for metastatic soft tissue sarcoma?

1 Answer available

Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

2 Answers available

How should you manage a COVID-19 infected/suspected patient who is receiving chemotherapy and cannot interrupt or delay their cancer treatment?

2 Answers available

How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?

Should staging and treatment decisions be made based on imaging alone?

2 Answers available

How should our selection for neoadjuvant chemotherapy for breast cancer change in light of COVID-19?

2 Answers available

In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?

Acknowledging that there is no time for good trials yet in this setting

1 Answer available

Given the current COVID-19 pandemic, how long would you delay mastectomy post neoadjuvant chemotherapy?

Would the recommendation differ based on HR+ vs. TNBC vs HER2+ classification? Would you recommend against immediate breast reconstruction?

1 Answer available

For patients who meet criteria to be treated with 3 months of CAPEOX based on IDEA study, is it reasonable to use capecitabine alone for 3 months and drop oxaliplatin during the COVID pandemic?

Given that majority of benefit is derived from the capecitabine, would this be an acceptable option to decrease patient contact with the healthcare sy...

1 Answer available

What are best practices for medical oncology clinics during the COVID-19 pandemic?

1 Answer available

How would you approach adjuvant therapy in a patient with HR+ breast cancer with a high RS (>25) given the current COVID-19 pandemic?

Would you consider delaying chemotherapy and proceeding only with endocrine for now?

2 Answers available

How should you manage a coronavirus infected/suspected patient who is receiving radiotherapy and cannot interrupt or delay their cancer treatment?

How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...

7 Answers available

What are the current official guidelines regarding managing patients during COVID-19?

3 Answers available

Are you more inclined to use neoadjuvant endocrine therapy over neoadjuvant chemotherapy or upfront surgery for your ER+HER2- breast cancer patients during the COVID19 pandemic?

Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, bu...

1 Answer available

Should we consider deferring adjuvant chemotherapy for resected early-stage NSCLC in light of COVID-19?

If so, how long is too long to wait?

1 Answer available

Should we delay adjuvant breast radiotherapy for early stage breast cancers as the COVID-19 situation evolves?

Would your practice vary based on hormone receptor or Her2 status?

5 Answers available

What is the longest acceptable interval between radical orchiectomy and adjuvant BEP for Stage IIB/III pure seminoma in the age of COVID-19?

2 Answers available

Should I wear gloves during a routine physical exam on an asymptomatic patient with no risk factors for COVID-19?

1 Answer available

How would you approach missed doses of fulvestrant due to COVID-19?

1 Answer available

What measures should we take regarding routine follow-up visits for well patients in surveillance during the coronavirus pandemic?

When a physical exam is important and telehealth is not a good option, should we be proactive and reschedule or should we continue to see them as sche...

2 Answers available

Should we be stopping new starts of patients who can be triaged for 2-3 months like prostate cancers on ADT when significant community spread of COVID-19 is detectable in our area?

Mitigating the spread of COVID-19 is of utmost priority now that containment measures have failed. Social distancing will help "flatten the curve" of ...

9 Answers available

Is there any consensus or guidance on how to manage germ cell tumor patients in the COVID-19 era?

1 Answer available

What scenarios, if any, are you delaying adjuvant chemotherapy in light of the COVID-19 outbreak?

1 Answer available

Have your treatment recommendations for urothelial cancer patients changed given the ongoing COVID19 pandemic?

Would you forego neoadjuvant chemotherapy? Are you using growth factor support differently? Any changes to immunotherapy? Other considerations?

2 Answers available

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers available